Nasdaq

iRhythm Technologies Presents AVALON Study Findings Demonstrating Superiority of Zio LTCM in Commercially Insured Patients at HRS2025

iRhythm Technologies, Inc. has announced findings from the AVALON study, presented at HRS2025, highlighting the effectiveness of its Zio long-term continuous monitoring (LTCM) service in a younger, ...
Seeking Alpha

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...
Seeking Alpha

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority

In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, ...